MaxCyte, Inc. Consolidation of Trading Lines (6770D)
February 21 2020 - 1:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 6770D
MaxCyte, Inc.
21 February 2020
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT
CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION,
OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE
OR DISPOSE OF ANY SECURITIES IN MAXCYTE, INC. OR ANY OTHER ENTITY
IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS
DISTRIBUTION SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION
WITH, ANY INVESTMENT DECISION IN RESPECT OF MAXCYTE, INC.
MaxCyte, Inc.
("MaxCyte" or the "Company")
Consolidation of Trading Lines
Gaithersburg, Maryland - 21 February 2020: MaxCyte (LSE: MXCT,
MXCS), the global clinical-stage cell-based therapies and life
sciences company, announces the consolidation of the two lines of
Common Stock into a single unrestricted line of Common Stock
(MXCT.L). This will be effected by the transfer of all stock
comprising the Regulation S restricted trading line MXCS.L to the
unrestricted Common Stock (MXCT.L) trading line.
This is in accordance with the Company's previously stated
intention that the two lines of Common Stock would be consolidated
following expiration of the distribution compliance period in
relation to new shares issued by the Company on 28 February 2019
and 1 March 2019. (Further details on the restrictions and
distribution compliance period are set out below). The
consolidation is intended to help both trading liquidity and
transparency for shareholders. The move will result in the
cancellation of trading of the Regulation S restricted trading line
MXCS.L (ISIN Number USU575801175 ).
Currently MaxCyte common stock of $0.01 par each ("Common
Stock") are held as:
(i) unrestricted Common Stock trading under the symbol MXCT.L
(ISIN number US57777K1060)
(ii) restricted Common Stock trading under the symbol MXCS.L (
ISIN number USU575801175)
The number of unrestricted shares of Common Stock currently
trading under the symbol 'MXCT.L' is 51,444,847 and the number of
restricted shares of Common Stock currently trading under the
symbol 'MXCS.L' is 5,958,736.
From 2 March 2020, all 57,403,583 MaxCyte Common Stock will be
held as unrestricted shares in MXCT.
Further details regarding the restricted shares
As stated in the Company's circular dated 6 February 2019, the
Company has intended to transfer the restricted shares held by
non-affiliates (as defined under the US Securities Act of 1933, as
amended (the "Securities Act")) of the Company (including those
holders who are affiliates only by virtue of their position as an
officer or director of the Company) to the unrestricted line of
Common Stock. As this includes all of the restricted shares the
Company will also be cancelling the restricted trading line.
While the restricted shares on the trading line MXCS.L are
identical in all respects to the Company's Common Stock, free from
all liens, charges and encumbrances of any kind, during the
"distribution compliance period", (as set out under Regulation S
under the Securities Act) they are subject to the conditions listed
under section 903(b)(3), or Category 3, of Regulation S. This
restricted line of Common Stock under the symbol MXCS.L is held in
the CREST system and has been segregated within CREST identified
with the marker "REG S" and ISIN USU575801175 . Those shares may
not be offered or sold to, or for the account or benefit of, US
Persons (as defined under the Securities Act) during the
distribution compliance period.
The distribution compliance period will end on 28 February 2020
and the restricted Regulation S trading line with the symbol MXCS.L
and ISIN USU575801175 will cease trading at 4:30pm on Friday 28
February 2020. All shareholders on the MXCS.L share register at
6:00pm on Friday 28 February 2020 will have their shareholding in
Common Stock transferred to the non-restricted share register. From
Monday 2 March 2020 all MaxCyte Common Stock will trade under the
symbol MXCT.L, ISIN number US57777K1060 . Shareholders who hold
shares in paper certificate format will be sent replacement share
certificates within ten business days.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. Through its life sciences business,
MaxCyte leverages its Flow Electroporation(R) Technology to enable
its biopharmaceutical partners to advance the development of
innovative medicines, particularly in cell therapy. MaxCyte has
placed its technology worldwide, including with all of the top ten
global biopharmaceutical companies. The Company now has more than
100 partnered programme licenses in cell therapy with more than 70
licensed for clinical use. The Company has now signed eight
clinical/commercial licenses with leading cell therapy developers
and the potential pre-commercial milestones from these
relationships now exceeds $650 million. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products. MaxCyte is also developing novel CARMA
therapies, with its first drug candidate in a Phase I clinical
trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic
platform for autologous cell therapy for the treatment of solid
cancers. MaxCyte has established CARMA as a wholly owned subsidiary
to facilitate independent investment and new partnerships to
advance t he CARMA platform. For more information, visit
www.maxcyte.com .
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
These materials may not be published, distributed or transmitted
by any means or media, directly or indirectly, in whole or in part,
in or into the United States or any other jurisdiction where their
publication or distribution would be unlawful. These materials are
for information purposes only and do not constitute an offer to
sell, or a solicitation of an offer to buy, securities in the
United States or any other jurisdiction where such offer or
solicitation is not authorised or to any person to whom it is
unlawful to make such offer or solicitation.
Securities may not be offered or sold in the United States
absent (i) registration under the Securities Act or (ii) an
available exemption from registration under the Securities Act. The
securities mentioned herein have not been, and will not be,
registered under the Securities Act and will not be offered to the
public in the United States.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSESEFSESSEEE
(END) Dow Jones Newswires
February 21, 2020 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024